Evidence map›Paper›PMID 39592887›Full record

ArticleCPT: pharmacometrics & systems pharmacology2025

MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis.

Marilyn A Huestis, William B Smith, Cathrine Leonowens, Rebecca Blanchard, Aurélien Viaccoz, Erin Spargo, Nicholas B Miner, Berra Yazar-Klosinski

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marilyn A HuestisInstitute of Emerging Health Professions, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-2137-4645
William B SmithAlliance for Multispecialty Research, LLC, Knoxville, Tennessee, USA.
Cathrine LeonowensIndependent Consultant, Durham, North Carolina, USA.
Rebecca BlanchardRebecca Blanchard Consulting, LLC, Allentown, Pennsylvania, USA.
Aurélien ViaccozLykos Therapeutics, San Jose, California, USA.
Erin SpargoNMS Labs, Horsham, Pennsylvania, USA.ORCID 0009-0002-3282-7988
Nicholas B MinerLykos Therapeutics, San Jose, California, USA.ORCID 0000-0002-4753-7548
Berra Yazar-KlosinskiLykos Therapeutics, San Jose, California, USA.ORCID 0000-0001-5972-006X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Midomafetamine (3,4-methylenedioxymethamphetamine [MDMA]) is under the U.S. Food and Drug Administration review for treatment of post-traumatic stress disorder in adults. MDMA is metabolized by CYP2D6 and is a strong inhibitor of CYP2D6, as well as a weak inhibitor of renal transporters MATE1, OCT1, and OCT2. A pharmacokinetic phase I study was conducted to evaluate the effects of food on MDMA pharmacokinetics. The results of this study, previously published pharmacokinetic data, and in vitro data were combined to develop and verify MDMA population pharmacokinetic and physiologically based pharmacokinetic models. The food effect study demonstrated that a high-fat/high-calorie meal did not alter MDMA plasma concentrations, but delayed T

Indexed as

Models, BiologicalN-Methyl-3,4-methylenedioxyamphetamineAdolescentAdultCytochrome P-450 CYP2D6Drug InteractionsFemaleHumansMaleMiddle AgedYoung AdultCytochrome P-450 CYP2D6N-Methyl-3,4-methylenedioxyamphetamine

Identifiers

PMID39592887
PMCPMC11812931

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.